ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has issued a concerning alert regarding a batch of stomach acid treatment medicine deemed substandard.
According to reports, the Drug Regulatory Authority of Pakistan (DRAP) has initiated a product recall alert for DXL 60 mg capsules, commonly used for stomach acid treatment. DXL, composed of dexlansoprazole, has come under scrutiny following a submission from the provincial quality control board.
The alert highlights that batch 2336 of DXL capsules has failed to meet the required standards and has consequently been deemed substandard. The provincial authority in Balochistan, DTL, has officially declared this batch unfit for consumption.
DXL Capsules, crucial for alleviating stomach acidity, have failed to meet the standard test requirements, raising concerns about their efficacy and potential health implications.
As a precautionary measure, DRAP has imposed a ban on the market supply of the affected DXL capsule batch. Furthermore, the pharmaceutical company responsible has been instructed to promptly withdraw the affected batch from circulation.
DRAP has urged chemists to return the affected capsules to the company and has deployed provincial drug regulatory authority teams to intensify market surveillance efforts, ensuring compliance with the recall directive.